Mint Med Review: What Its GLP-1 Documentation Establishes—and What It Does Not

A medication name is not a complete evidence trail. For someone considering Mint Med, the relevant questions extend beyond whether semaglutide or tirzepatide has been studied: Which preparation would be prescribed, who evaluates the patient, which pharmacy dispenses it, and what does the subscription actually promise? Mint Med’s public documentation establishes an online service offering compounded GLP-1 treatment subject to clinical approval. It does not establish that its own preparations or care program produce the results reported in drug trials.

This review examines public pages consulted October 19, 2026, separating documented service features from commercial claims and clinical evidence. The documents describe meaningful elements of care, including medical-history screening, secure messaging and pharmacy fulfillment. They also contain discrepancies involving prices, payment timing, state availability, cancellation channels and shipping. Those inconsistencies do not prove poor treatment, but they make a single advertisement an inadequate basis for understanding the full arrangement.

At a glance

Platform, not the medical practice: Mint Med’s terms say MINT MED, LLC connects patients with independent licensed healthcare providers and does not itself provide medical services.
Sources: [10]
Multiple advertised prices: Compounded semaglutide appears at $89 monthly on one page and $129 monthly on another; intake lists a starting price of $106 monthly.
Sources: [13] [6] [7]
Compounded, not FDA approved: Mint Med identifies its compounded semaglutide and tirzepatide as not FDA approved. FDA approval of a specific medicine does not extend to this platform or its compounded preparations.
Sources: [9] [1]
Recurring charges: Intake states that plans automatically renew at checkout’s price and interval. The formal policy requires cancellation at least 48 business hours before scheduled order processing.
Sources: [7] [5]
Named fulfillment partners: The contact page lists RxCompoundStore Pharmacy in Fort Lauderdale, Florida, and Southend Pharmacy in Houston, Texas, as fulfillment partners.
Sources: [12]

Start with the organization behind the offer

Mint Med describes itself as a fully online telehealth platform covering weight loss, energy and wellness, sexual wellness, and hair regrowth. Its terms assign medical services to independent licensed providers in the patient’s state rather than to the platform. That distinction matters when evaluating evidence: a platform’s description of access and coordination is not the same as documentation of an individual clinician’s decisions or a pharmacy’s finished preparation.

The institutional page names Roderick Huff, MD, as founder and attributes more than two decades of experience to him. Separately, intake says every case receives review by a U.S. physician board-certified in obesity medicine. These are provider representations, not independently verified credentials in this review. They also should not be read as proof that every subsequent message, follow-up interaction or support response comes from that physician.

There is an unresolved identity discrepancy: the terms name MINT MED, LLC, while the privacy policy identifies Glow Medispa, LLC doing business as Mint Med. The consulted documentation does not explain their relationship. As our guide to what provider documents can prove explains, such documents can establish stated responsibilities without independently validating performance. Here, patients have reason to request clarification about the entity handling payment, records and complaints.

Sources: [10] [15] [9] [11] [7]

The compounded offering is not the same evidence object as a studied drug

Mint Med advertises compounded semaglutide and compounded tirzepatide. Its semaglutide page includes injection supplies, documenting an injectable presentation, but the consulted material does not clearly specify the tirzepatide route. Mint Med says the dispensing pharmacy, formulation, concentration, packaging and labeling may vary. Those details are consequential evidence gaps: an ingredient name alone does not identify the exact product a patient will receive or establish that it matches a preparation studied in a clinical trial.

Mint Med acknowledges that these compounded preparations are not FDA approved and have not undergone FDA review for safety, effectiveness or quality. FDA recommends compounded drugs for patients whose medical needs cannot be met by an FDA-approved drug, with a prescription and a state-licensed pharmacy. Nonapproval alone does not demonstrate clinical inequivalence, but neither does research involving a specific studied drug automatically validate a compounded preparation. Our approved-versus-compounded evidence guide explains that distinction.

Mint Med also describes a customizable, non-GLP-1 MintFit Weight Loss Kit that may include low-dose naltrexone, bupropion, metformin ER, inositol or orlistat, depending on clinical needs. That is a separate offering, not evidence about the GLP-1 program. Likewise, branded medicines named in intake—such as Wegovy, Ozempic, Zepbound and Mounjaro—appear as examples of prior medication use. Their appearance there does not establish that Mint Med sells those products.

Sources: [7] [6] [9] [1]

What the intake process documents about clinical review

The intake process asks about symptoms, medical history and health goals before recommendations. It also asks whether applicants used a GLP-1 medication in the preceding two months. The screening includes gastrointestinal and pancreatic history, diabetes-related conditions, personal or family thyroid cancer history, MEN-2 history, and eating disorders. These questions document a screening process; they do not reveal how answers are adjudicated, establish individual eligibility or demonstrate the completeness of an eventual clinical assessment.

Consultation format depends on state requirements. Mint Med says patients in states requiring live audio or video are prompted to schedule a visit, while asynchronous review can produce a recommendation through secure patient chat where permitted. A semaglutide page says portal access and the medical questionnaire arrive by email after payment, and estimates questionnaire completion at three to five minutes. That completion estimate describes paperwork, not the time needed for a clinical evaluation.

Review estimates differ substantially. The how-it-works page promises review within six business hours; another product section says within 24 business hours, normally with same-day approvals; another says normally within 48 business hours and acknowledges variability. The documentation does not establish one universal turnaround. It also leaves BMI requirements, laboratory requirements and a mandatory follow-up schedule unspecified. For an evidence-focused reader, a fast review claim should not substitute for an explanation of what review includes.

Sources: [9] [7] [6] [8]

Prices are documented, but not consistently

Mint Med publishes concrete prices, so describing cost as simply unavailable would be misleading. The problem is that its pages do not agree. One compounded semaglutide listing advertises $89 billed monthly; another advertises $129 billed month to month. Intake instead lists semaglutide starting at $106 monthly and tirzepatide starting at $145 monthly without explaining the associated commitment. The product listings below preserve their stated billing intervals rather than treating monthly equivalents as monthly payment options.

A second semaglutide page also advertises prepaid options at $119 per month for three months and $109 per month for six months. The three-month offer specifically describes a prepaid three-month supply, free cold shipping and supplies, all doses included, and a full refund if not approved. Across listings, “Lifetime Price” and “All Doses Included” are advertising claims; the consulted documentation does not resolve the full conditions of the lifetime-price promise or which conflicting offer checkout will apply.

The $129 semaglutide page says its monthly price includes medication if prescribed, injection supplies, two-day cold shipping and clinician visits, with no coupon, membership, access or separate clinician-visit fee. The homepage also lists intake review, history and eligibility assessment, a visit if needed, unlimited care-team messaging and ongoing support. Terms nevertheless make services cash-pay, do not accept insurance and assign third-party costs to the patient. Confirm inclusions for the exact chosen plan rather than transferring one page’s bundle to every offer.

Selected product-page offers; conflicting prices elsewhere remain unresolved
Compounded medicine	Advertised monthly amount	Stated collection schedule
Semaglutide, monthly listing	$89; lifetime price, all doses included	$89 every month; monthly delivery
Semaglutide, three-month prepaid listing	$85; lifetime price, all doses included	$255 every three months
Semaglutide, six-month prepaid listing	$79; lifetime price, all doses included	$474 every six months
Tirzepatide, monthly listing	$119; lifetime price, all doses included	$119 every month; monthly delivery
Tirzepatide, three-month prepaid listing	$110; lifetime price, all doses included	$330 every three months
Tirzepatide, six-month prepaid listing	$99; lifetime price, all doses included	$594 every six months

Sources: [13] [6] [14] [7] [9] [10]

Payment and cancellation language need reconciliation

The homepage says payment is collected upfront to begin clinical review, with medication prescribed only if medically appropriate. A product section instead advertises a free, no-obligation evaluation and says payment is processed only after approval. Those are materially different payment sequences. The how-it-works page promises a full, immediate refund for ineligible applicants, but that wording does not establish when money will reach a bank account. Obtain the applicable sequence before authorizing payment.

Intake says subscriptions renew automatically at the checkout price and interval until canceled. It permits cancellation in the account or by emailing help@mintmed.com up to 48 business hours before renewal. The formal policy instead requires the official cancellation form and receipt at least 48 business hours before scheduled order processing; requests inside that window cannot be honored. Because the trigger date and channel differ, relying on an ordinary email alone leaves a documented uncertainty.

Cancellation also does not establish refund eligibility. The policy excludes refunds once an order is processed, even before shipment, and does not accept returns after a prescription has been filled and dispensed. Consultation fees become nonrefundable after the visit unless the provider determines medical ineligibility. For prepaid terms of three, six or twelve months, early cancellation requires paying the difference between promotional and full pricing. The public text does not fully explain that adjustment’s calculation.

Sources: [9] [6] [7] [5] [8]

Pharmacy fulfillment has several separate clocks

Mint Med explicitly says it coordinates care but does not manufacture, compound or dispense medication. Its contact page names RxCompoundStore Pharmacy in Fort Lauderdale and Southend Pharmacy in Houston as fulfillment partners. That identifies possible participants, not the pharmacy assigned to a particular patient or the exact preparation it will supply. The consulted documentation does not independently verify pharmacy credentials, accreditation or inventory, and dispensing a medication should not be confused with identifying who compounded it.

The homepage separates prescription processing—24 to 48 business hours after approval—from shipping, typically five to seven business days. Elsewhere the product page describes two-day cold shipping and, in another section, free overnight shipment once approved. These statements do not establish a single arrival deadline. Intake says the pharmacy ships cold-packed medication to the patient’s address, with no in-person pickup, and tracking becomes available only after the pharmacy ships.

A useful confirmation therefore separates clinical approval, pharmacy processing, dispatch and transit rather than adding every advertised estimate into a presumed guarantee. Our guide to reading cold-chain claims explains why dispatch and arrival are different events. FDA also gives an explicit precaution: do not use an injectable GLP-1 drug that arrives warm or with insufficient refrigeration; contact the provider or dispensing pharmacy to resolve the concern. Free shipping does not answer a temperature-handling question.

Sources: [6] [12] [9] [7] [1]

Availability and support are more specific than “online”

Terms limit services to U.S. residents who are at least 18, with some services potentially requiring age 21, and require patients to be in a state where Mint Med operates. Geographic documentation conflicts: the homepage claims 35 states but lists 36 abbreviations, including California; the contact page lists 35 and omits California. Neither statement establishes nationwide availability. A California resident, in particular, should confirm eligibility directly rather than assuming that one list overrides the other.

For ongoing contact, intake directs medication questions, billing questions, address changes, medical questions and support to the Elation Health Patient Portal. It explicitly says Facebook and Instagram are not secure medical-support channels and do not have access to pharmacy shipping information. The contact page also offers calls or texts at +1-513-826-6142 and email at help@mintmed.com, with a U.S.-based care team available Monday through Friday, 9 a.m. to 5 p.m. EST.

Unlimited messaging and ongoing support are useful documented inclusions, but they do not establish an immediate human response or a defined clinical follow-up schedule. NIDDK describes follow-up as assessment of response and tolerability, not merely continued payment. Mint Med’s public material leaves the required frequency and format unclear. Before enrollment, ask who reviews treatment concerns, how they are escalated, and whether scheduled reassessment is included in the particular plan being purchased.

Sources: [10] [9] [12] [7] [2]

What would strengthen the evidence for this service

Clinical trials of semaglutide and tirzepatide address specific study populations, preparations, routes and treatment conditions. They are not performance reports for Mint Med. The consulted public documentation does not provide provider-specific clinical outcome data establishing effectiveness or safety for its care model and compounded products. Testimonials and promotional result claims cannot fill that gap. Our explanation of why trials are not company performance reports offers a framework for reading those claims without dismissing relevant drug research.

For Mint Med, stronger decision documentation would connect the offer to a named dispensing pharmacy, the prescribed formulation and presentation, clear instructions, a follow-up plan, and consistent financial terms. Those are practical requests rather than demands for a guaranteed outcome. FDA has received reports of compounded-medication measurement or administration errors, some involving hospitalization. Patients should clarify instructions with their prescriber or pharmacist rather than calculating doses from a review; those reports do not establish a Mint Med-specific event rate.

The most useful next step is a written confirmation matching the checkout offer: medicine and presentation, billing interval, included services, payment timing, pharmacy assignment, expected fulfillment stages and cancellation route. That document would not prove clinical effectiveness, but it would resolve several uncertainties that currently complicate informed comparison. Separate the question “Is the service clearly described?” from “What evidence supports this exact treatment?” Both matter, and neither can be answered by a low advertised price alone.

Sources: [3] [4] [1] [13] [6] [9] [7] [5]

Questions & answers

Does Mint Med offer branded Wegovy or Zepbound?

The documented product offers are compounded semaglutide and tirzepatide. Intake mentions Wegovy, Zepbound and other brands when asking about recent GLP-1 use, but those examples do not establish branded-product availability. Ask specifically which product and preparation the proposed prescription would cover.

Sources: [7] [13] [14]

What is Mint Med’s monthly semaglutide price?

There is no single consistent advertised figure: product pages show $89 and $129 monthly, while intake says starting at $106 monthly. Prepaid offers differ too. Confirm the actual checkout charge, renewal interval, included services and applicable price conditions rather than assuming the lowest listing applies universally.

Sources: [13] [6] [7]

Will Mint Med charge me before a clinician approves treatment?

Its pages disagree. The homepage says payment is collected upfront to start review; a product section says payment is processed only after approval. A separate page promises a full, immediate refund for ineligibility. Ask which sequence governs your order and how an applicable refund is handled.

Sources: [9] [6] [8]

How should I cancel a Mint Med subscription?

The formal policy requires the official cancellation form at least 48 business hours before scheduled order processing. Intake also mentions account cancellation or email before renewal, leaving a channel discrepancy. Seek confirmation of receipt and the effective date. Canceling does not automatically create a refund, and prepaid plans have an early-cancellation price adjustment.

Sources: [7] [5]

Can I choose a local pharmacy for pickup?

The documented intake arrangement is cold-packed shipment from a licensed partner pharmacy to the patient’s address, with nothing to collect in person. Mint Med lists two fulfillment partners, but the consulted material does not establish a local-pickup option or unrestricted pharmacy choice. Confirm the assigned pharmacy before relying on an alternative arrangement.

Sources: [7] [12]

Does Mint Med accept insurance or guarantee HSA/FSA acceptance?

The terms say services are cash-pay and insurance is not accepted. Although a heading advertises HSA/FSA eligibility, the consulted documentation does not explain qualification requirements, supporting paperwork or guaranteed acceptance. Insurance coverage and account reimbursement are separate questions; obtain the relevant plan or account administrator’s requirements rather than treating a marketing heading as confirmation.

Sources: [10] [6]

Our assessment

Mint Med documents a recognizable telehealth pathway: medical-history intake, independent clinician review, compounded prescriptions when appropriate, partner-pharmacy shipment and secure support. It also publishes specific prices and acknowledges compounded drugs’ lack of FDA approval. The principal weakness is not an absence of descriptions but their inconsistency across pages. Prices, charge timing, turnaround estimates, geographic coverage and cancellation instructions require reconciliation. Public documentation does not establish Mint Med-specific clinical outcomes or validate its preparations through trials of other products. A reasonable decision depends on obtaining a coherent written offer and treatment process—not assuming either that advertising proves effectiveness or that documentation gaps prove inadequate care.

Visit Mint Med’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

Mint Med Review: What Its GLP-1 Documentation Establishes—and What It Does Not

At a glance

01Start with the organization behind the offer

02The compounded offering is not the same evidence object as a studied drug

03What the intake process documents about clinical review

04Prices are documented, but not consistently

05Payment and cancellation language need reconciliation

06Pharmacy fulfillment has several separate clocks

07Availability and support are more specific than “online”

08What would strengthen the evidence for this service